Qiagen Marseille SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Qiagen Marseille SA Summons AB Analitica SRL Before the Venice Court
Qiagen Marseille SA announced that the company summoned the Italian company AB Analitica S.r.l. before the Venice Court on March 15, 2013. According to Qiagen Marseille SA, AB Analitica's kits for the detection of the JAK2 mutation, which are known as GeneQuality JAK2, RealQuality RS-JAK2 V617F and RealQuality RS-JAK2 V617F Q, would infringe various claims of European Patent No. 1 692 281 exclusively licensed to Qiagen Marseille SA. The plaintiff is therefore seeking, inter alia, a permanent injunction against AB Analitica and the recovery of the damages suffered as a consequence to the infringement. Although no decision has yet been issued on the merits of Qiagen Marseille SA's claims vis a vis AB Analitica, this action follows a search order granted by the Venice Court, whereby Qiagen Marseille SA has been able to collect relevant evidence at the premises of the defendant in Padua.
Latest Key Developments in Biotechnology
- Flex Pharma Inc announces pricing of initial public offering
- PAREXEL International Corp lowers FY 2015 revenue guidance; raises FY 2015 EPS guidance; gives Q3 2015 EPS guidance; revenue guidance below analysts' estimates
- Radius Health Inc announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares
- Vaccinogen Inc closes second tranche of $80 mln financing at $5.50 per unit
- Share this
- Digg this